Mushure mekupindura mubvunzo uyu nemutauro mumwecheteyo: Passage: As of 2019, twelve disease-modifying medications are approved by regulatory agencies for relapsing-remitting multiple sclerosis (RRMS). They are interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, and cladribine.Their cost effectiveness as of 2012 is unclear. In March 2017 the FDA approved ocrelizumab, a humanized anti-CD20 monoclonal antibody, as a treatment for RRMS, with requirements for several Phase IV clinical trials. In RRMS they are modestly decreasing the number of attacks. The interferons and glatiramer acetate are first-line drugs yet are clear and are equivalent to those of other drugs. However, the risk of treating severe adverse reactions is roughly 30%.
interferon beta-1a